Nuclear medicine diagnosis of neuroendocrine tumors;Nuklearmedizinische diagnostik neuroendokriner tumoren

Onkologe

Volumn 10, Issue 6, 2004, Pages 598-610

  Baum, R P ^a   Hofmann, M ^b  

^a ZENTRALKLINIK BAD BERKA   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Carcinoid; GEP tumors; Neuroendocrine tumors Carcinomas; Nuclear medicine diagnosis; Somatostatin receptor scintigraphy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 5 HYDROXYTRYPTOPHAN; DEPREOTIDE TC 99M; FLUORODEOXYGLUCOSE F 18; GALLIUM EDETATE GA 68; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR; YTTRIUM 90;

CARCINOID; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; ECHOGRAPHY; GASTRINOMA; GLUCAGONOMA; HUMAN; IMMUNOHISTOCHEMISTRY; INSULINOMA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RECEPTOR DENSITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR LOCALIZATION; TUMOR SCINTISCANNING;

EID: 3142693877     PISSN: 09478965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Adams S, Baum RP, Adams M et al. (1997) Zur klinischen Wertigkeit der Somatostatinrezeptorszintigraphie. Med Klin 92:138-143
2. Adams S, Baum RP, Hertel A (1998) Intraoperative Gamma Probe Detection of Neuroendocrine Tumors. J Nucl Med 39:1155-1160
3. 111In-DTPA-D-Phel-octreotide. Eur J Nucl Med 27:628-637
4. 99mTc depreotide in the evaluation of solitary pulmonary nodules. Chest 117:1232-1238
5. 111Inpentetreotide scintigraphy: procedure guidelines for tumor imaging. Eur J Nucl Med Mol Imaging 30:BP140-BP147
6. 111In-labelled octreotide derivatives. Eur J Nucl Med 27:1318-1325
7. 111In- octreotide. J Nucl Med 41:1113-1119
8. Dörr U, Räth U, Sautter-Bihl ML et al. (1993) Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue. Eur J Nucl Med 20:431-433
9. Ehrlich P (1900). Croonian Lecture - on Immunity. Proc R Soc London 66:424
10. Eriksson B, Bergstrom M, Sundin A, Juhlin C, Orlefors H, Oberg K, Langstrom B (2002) The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci 970:159-169
11. Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H, Moser E, Nitzsche E. Whole-body F-18 DOPA PET for detection of gastrointestinal carcinoid tumors (2001). Radiology 220:373-380
12. Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand Ga-68 DOTATOC: preliminary data. Eur J Nucl Med 28:1751-1757
13. 111In-pentatreotide in gastroenteropancreatic endocrine tumors (GEP). Eur J Nucl Med 19:736
14. Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, de Camps J, Schran H, Chen T, Smith MC, Bouterfa H, Valkema R, Krenning EP, Kvols LK, Pauwels S (2003) Y-86 DOTA-D-Phe1-Tyr3-octreotide (SMT487)-a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 30:510-518
15. Joseph K, Stapp J, Reinecke J et al. (1992) Rezeptorszintigraphie bei endokrinen gastroenteropankreatischen Tumoren. Dtsch Med Wochenschr 117:1025-1028
16. Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkom U (2003). Evaluation of positron emission tomography imaging using Ga-68 DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to In-111-DT-PAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 5:42-48
17. Krenning EP, Bakker WH, Breeman WAP et al. (1989) Localisation of endocrine related tumors with radioiodinated analogue of somatostatin. Lancet 1:242-245
18. 123l-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716-731
19. Krenning EP, Kwekkeboom DJ, Oei HY et al. (1994) Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Ann NY Acad Sci 733:416-424
20. Kwekkeboom DJ, Krenning EP (1996) Somatostatin receptor scintigraphy in patients with carcinoid tumors. World J Surg 20:157-161
21. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging (2002) Semin Nucl Med 32:84-91
22. Lamberts SWJ, Bakker WH, Reubi JC et al. (1990) Somatostatin receptor imaging in the localization of endocrine tumors. N Engl J Med 323:1246-1249
23. Maecke HR, Behe M (1996). New octreotide derivatives labelled with technetium-99m [abstract]. J Nucl Med 37:1144
24. Meijer WG, van der Veer E, Jager PL, van der Jagt EJ, Piers BA, Kema IP, de Vries EG, Willemse PH (2003) Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med 44:184-191
25. Patel YC, Amherdt M, Orci L (1982) Quantitative electron microscopic autoradiography of insulin, glucagon and somatostatin binding sites on islets. Science 217:1155-1156
26. Reubi JC, Maurer R (1985) Autoradiographic mapping of somatostatin receptors in the rat CNS and pituitary. Neuroscience 15:1183-1193
27. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Maecke H (2000) Affinity profiles for human somatostatin receptor subtypes SST1.SST5 of somatostatin tracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27:273-282
28. Signore A, Annovazzi A, Chianelli M et al. (2001) Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med 28:1555-1565
29. Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H (1996) Combined diagnostic imaging with 1-131 metaiodobenzylguanidine and In-111 pentetreotide in carcinoid tumours. Eur J Cancer 32A:1924-1932
30. Zuetenhorst JM, Hoefnagel CA, Boot H, Valdes Olmos RA, Taal BG (2002) Evaluation of In-111 pentetreotide, l-131 MlBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 23:735-741